Altimmune (ALT) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 0.47%.

  • Altimmune's Return on Capital Employed rose 2600.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year increase of 2600.0%. This contributed to the annual value of 0.63% for FY2024, which is 1400.0% down from last year.
  • As of Q3 2025, Altimmune's Return on Capital Employed stood at 0.47%, which was up 2600.0% from 0.57% recorded in Q2 2025.
  • In the past 5 years, Altimmune's Return on Capital Employed registered a high of 0.25% during Q1 2021, and its lowest value of 0.78% during Q4 2024.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.5% (2023), whereas its average is 0.52%.
  • Per our database at Business Quant, Altimmune's Return on Capital Employed soared by 3000bps in 2021 and then tumbled by -2700bps in 2022.
  • Quarter analysis of 5 years shows Altimmune's Return on Capital Employed stood at 0.46% in 2021, then grew by 5bps to 0.44% in 2022, then fell by -23bps to 0.54% in 2023, then plummeted by -43bps to 0.78% in 2024, then skyrocketed by 39bps to 0.47% in 2025.
  • Its last three reported values are 0.47% in Q3 2025, 0.57% for Q2 2025, and 0.71% during Q1 2025.